<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892525</url>
  </required_header>
  <id_info>
    <org_study_id>ITSELF</org_study_id>
    <nct_id>NCT03892525</nct_id>
  </id_info>
  <brief_title>Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma</brief_title>
  <official_title>Phase Ib Study Evaluating the Safety and Efficacy of Intratumoral Agonistic Anti-CD40 (Selicrelumab) in Combination With Anti-PDL1 (Atezolizumab) in Patients With Refractory or Relapsed B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open, dose escalation phase Ib trial of intratumoral agonistic&#xD;
      anti-CD40 Ab (Selicrelumab intratumoral every 3 weeks for 3 cycles) in combination with&#xD;
      anti-PDL1 Ab (Atezolizumab 1200mg intravenous every 3 weeks) in patients with refractory or&#xD;
      relapsed B cell lymphoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    End of drug development&#xD;
  </why_stopped>
  <start_date type="Actual">July 4, 2019</start_date>
  <completion_date type="Actual">April 7, 2021</completion_date>
  <primary_completion_date type="Actual">April 7, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>optimal dose of intratumoral Selicrelumab in combination with flat doses of Atezolizumab IV</measure>
    <time_frame>21 days (1 cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete metabolic response rate (CMR)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete metabolic response rate (CMR)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete metabolic response rate (CMR)</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete metabolic response rate (CMR)</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall metabolic response rate (OMR)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall metabolic response rate (OMR)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall metabolic response rate (OMR)</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall metabolic response rate (OMR)</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall metabolic response (BOMR)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse event (SAE)</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Recurrent B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory B-Cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selicrelumab</intervention_name>
    <description>escalated dose in intratumoral injection, every 3 weeks, for 3 cycles</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>1200mg IV every 3 week until progression or relapse for maximum 1 year</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 and older&#xD;
&#xD;
          2. Histologically confirmed diagnosis of recurrent or refractory B-non-Hodgkin's lymphoma&#xD;
             (NHL)&#xD;
&#xD;
          3. At least one injectable lesion:&#xD;
&#xD;
             i) at least one nodal lesion amenable to intratumoral injection and biopsy (including&#xD;
             deep lesions accessible by interventional radiology either under US or CT-scan&#xD;
             guidance). The first injected lesion should be of at least 2 x 1.5 cm in diameter. The&#xD;
             subsequent lesions to be injected should be ≥1.5 cm in diameter. Extra nodal lesions&#xD;
             will not be considered as injectable lesion.&#xD;
&#xD;
             ii) OR One cutaneous lesion of at least ≥ 1 cm in diameter. Other extra nodal lesion&#xD;
             will not be considered as injectable lesion.&#xD;
&#xD;
          4. Patient must have a 18-F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) avid&#xD;
             lymphoma that can be followed by positron emission tomography (PET).&#xD;
&#xD;
          5. Bi-dimensionally measurable disease defined by at least one measurable lesion&#xD;
             according to Lugano criteria, with at least 1cm in its shortest diameter and 1.5cm in&#xD;
             largest diameter (different from the lesion that will be injected)&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1&#xD;
&#xD;
          7. Signed written informed consent&#xD;
&#xD;
          8. Life expectancy ≥ 3 months&#xD;
&#xD;
          9. Patients must have recovered to ≤ grade 1 from all toxicities related to prior&#xD;
             treatments excluding alopecia.&#xD;
&#xD;
         10. Patients must be naïve from immunotherapy with anti-PD1/PDL1 or agonistic anti-CD40&#xD;
             therapy&#xD;
&#xD;
         11. Adequate laboratory parameters:&#xD;
&#xD;
               -  Hb ≥ 9 g/dl&#xD;
&#xD;
               -  absolute neutrophil count (ANC) ≥ 1000/μL&#xD;
&#xD;
               -  Platelet count ≥ 50,000/μL&#xD;
&#xD;
               -  Total bilirubin &lt; 2.5 times the institutional upper limit of normal (ULN) (3.5 x&#xD;
                  ULN if liver involvement)&#xD;
&#xD;
               -  Hepatic enzymes (aspartate aminotransferase (AST), alanine aminotransferase (ALT)&#xD;
                  ) ≤ 2.5 x ULN (5 x ULN if liver involvement)&#xD;
&#xD;
               -  Serum creatinine &lt; 2.0 x ULN or creatinine clearance &gt;50 mL/mn&#xD;
&#xD;
               -  International Normalized Ratio (INR) and Partial Thromboplastin Time (PTT) &gt;1.5 ×&#xD;
                  ULN&#xD;
&#xD;
         12. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test within 72 hours prior to the start of study drug administration.&#xD;
&#xD;
         13. Persons of reproductive potential must agree to use an adequate method of&#xD;
             contraception throughout treatment and for at least 6 months after study drug is&#xD;
             stopped.&#xD;
&#xD;
             *Highly effective method includes: combined (estrogen and progestogen containing)&#xD;
             hormonal contraception associated with inhibition of ovulation 1 (oral/ intravaginal/&#xD;
             transdermal); progestogen-only hormonal contraception associated with inhibition of&#xD;
             ovulation 1 (oral/injectable/implantable); intrauterine device (IUD); intrauterine&#xD;
             hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner;&#xD;
             sexual abstinence&#xD;
&#xD;
         14. Patient covered by any social security system (France)&#xD;
&#xD;
         15. Patient who understands and speaks one of the country official language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Immature B cell malignancies (B-acute lymphoblastic leukemia (ALL), Burkitt lymphoma)&#xD;
             and T-cell lymphomas&#xD;
&#xD;
          2. History of severe allergic anaphylactic reactions to chimeric, human or humanized&#xD;
             antibodies, or fusion proteins or known hypersensitivity to Chinese hamster ovarian&#xD;
             (CHO) cell products or any component of the Atezolizumab formulation. Patients with a&#xD;
             known allergy to either of the drugs individually&#xD;
&#xD;
          3. Use of any standard or experimental anti-cancer drug therapy within 4 weeks prior to&#xD;
             the first scheduled treatment dose (C1D1).&#xD;
&#xD;
          4. History of treatment with anti-PD1 or anti-PDL1.&#xD;
&#xD;
          5. Significant immunosuppression from:&#xD;
&#xD;
               -  Concurrent, recent (≤ 2 weeks ago) or anticipated treatment with systemic&#xD;
                  corticosteroids at dose &gt;10mg/day of prednisolone (or equivalent)&#xD;
&#xD;
               -  Other immunosuppressive medications such as methotrexate, cyclosporine,&#xD;
                  azathioprine&#xD;
&#xD;
               -  Any immunosuppressive condition such as common variable hypogammaglobulinemia&#xD;
&#xD;
          6. Myocardial infarction within 6 months prior to first study drug, active cardiac&#xD;
             ischemia or New York Heart Association (NYHA) Grade III or IV heart failure, severe&#xD;
             arrhythmia, unstable arrhythmias, or unstable angina) or pulmonary disease (including&#xD;
             uncontrolled obstructive pulmonary disease and history of bronchospasm or other&#xD;
             according to investigator's decision)&#xD;
&#xD;
          7. left ventricular ejection fraction (LVEF) &lt; 45% as determined by echocardiography or&#xD;
             multiple uptake gated acquisition (MUGA) scan&#xD;
&#xD;
          8. Clinically significant history of liver disease, including viral or other hepatitis,&#xD;
             current alcohol abuse, or cirrhosis&#xD;
&#xD;
          9. Prior history of other cancer other than lymphoma within 2 years (except basal cell&#xD;
             carcinoma, in situ squamous and non-squamous cell carcinomas completely resected (R0)&#xD;
             and prostate cancers with normal results for more than 6 months)&#xD;
&#xD;
         10. Recent (&lt; 1 month ago) clinically significant infection, active tuberculosis or&#xD;
             antibiotics therapy&#xD;
&#xD;
         11. Central nervous system involvement with lymphoma, including parenchymal and&#xD;
             leptomeningeal disease. Patients with asymptomatic focal epiduritis on imaging might&#xD;
             be included with the Sponsor's approval.&#xD;
&#xD;
         12. Ongoing or history of autoimmune disease, including active non-infectious pneumonitis,&#xD;
             with the exception of alopecia, vitiligo, auto-immune endocrine deficiency with stable&#xD;
             hormone replacement therapy, controlled skin eczema and stable asymptomatic and&#xD;
             treated asthma. Patients with severe auto-immune disease in one of their parents,&#xD;
             siblings, or children will not be eligible.&#xD;
&#xD;
         13. Psychiatric, other medical illness or other condition that in the opinion of the PI&#xD;
             prevents compliance with study procedures or ability to provide valid informed consent&#xD;
&#xD;
         14. Use of anti-coagulant agents or history a significant bleeding diathesis. If a&#xD;
             superficial lymph node or subcutaneous mass is to be injected, patients on agents such&#xD;
             as non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, or clopidogrel are&#xD;
             eligible and these agents do not have to be withheld. For procedures with moderate or&#xD;
             significant risk of bleeding, long-acting agents such as aspirin or clopidogrel should&#xD;
             be discussed with the Sponsor and may need to be discontinued before Selicrelumab&#xD;
             therapy. Patients under preventive dose of low molecular weight heparin (LMWH) are&#xD;
             eligible if they can stop their treatment 24h prior the IT injection and restart 24h&#xD;
             after the injection. No anticoagulant restriction for patients with injected lesions&#xD;
             being superficial tumor lesions eligible for at least 5mn mechanical compression after&#xD;
             tumor biopsy &amp; injections (as in routine interventional radiology practice).&#xD;
&#xD;
         15. Subcapsular liver tumor lesions of tumor encased vessels or not eligible for&#xD;
             intratumoral biopsies or injections.&#xD;
&#xD;
         16. Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study&#xD;
             treatment, or anticipation of need for such a vaccine during Atezolizumab treatment or&#xD;
             within 5 months after the last dose of Atezolizumab&#xD;
&#xD;
         17. Prior allogeneic hematopoietic stem cell transplantation&#xD;
&#xD;
         18. Patients who have undergone a solid organ transplant&#xD;
&#xD;
         19. Documented infection with HIV&#xD;
&#xD;
         20. Positive serology to hepatitis B. Patients with previous and cured infections are not&#xD;
             eligible. Patients who are seropositive due to a history of hepatitis B vaccine are&#xD;
             eligible.&#xD;
&#xD;
         21. History or presence of an abnormal ECG that is clinically significant in the&#xD;
             investigator's opinion, including complete left bundle branch block, second- or third&#xD;
             degree heart block, or evidence of prior myocardial infarction&#xD;
&#xD;
         22. Person deprived of his/her liberty by a judicial or administrative decision&#xD;
&#xD;
         23. Person hospitalized without consent&#xD;
&#xD;
         24. Adult person under legal protection&#xD;
&#xD;
         25. Adult person unable to provide informed consent because of intellectual impairment,&#xD;
             any serious medical condition, laboratory abnormality or psychiatric illness&#xD;
&#xD;
         26. Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roch HOUOT, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>APHP - Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

